The World Health Organization has issued the first substantial rewrite of its dementia prevention guidance since 2019, and the practical headline for American households is that the list of things researchers have now formally assessed has grown considerably longer.
The second edition of the agency's guidelines on risk reduction of cognitive decline and dementia covers interventions addressing 20 potentially modifiable risk factors. The 2019 edition addressed 12. The new scope reaches into sleep, stroke, traumatic brain injury, vision impairment, HIV, and air pollution, none of which the earlier edition covered.
Only some of that new territory produced a recommendation. Reducing exposure to air pollution and using tailored programs that target several risk factors at once were judged to have evidence of benefit. For depression management, stroke, traumatic brain injury, vision impairment, sleep and HIV, WHO concluded the evidence was not sufficient to recommend interventions specifically for reducing dementia risk, even though those conditions clearly warrant treatment for other reasons.
The Headline Number Is a Ceiling, Not a Promise
WHO states that up to 45 percent of dementia risk can be attributed to modifiable factors. That figure deserves careful handling, because it is the number most likely to be misread.
It is a population attributable estimate. It describes what share of dementia cases across a whole population might be prevented or delayed if the identified risk factors were eliminated everywhere. It does not mean any individual who addresses those factors reduces personal risk by 45 percent, and it does not mean dementia is preventable in any particular person.
The agency's announcement notes that more than 57 million people live with dementia worldwide, with nearly 10 million newly diagnosed each year, and that Alzheimer's disease accounts for an estimated 60 to 70 percent of cases. WHO puts the annual global economic cost at about 1.3 trillion dollars, roughly half of it unpaid care by families and friends. There is still no widely available treatment that halts the underlying disease, which is the reason prevention occupies so much of the guidance.
The recommendations were developed using systematic evidence reviews and the GRADE method, a standard approach to rating how certain the evidence is. The agency also identifies where evidence remains insufficient, which is as informative as the recommendations themselves.
The Guidance Groups Actions into Four Categories
The full guideline document organizes interventions in a way that maps reasonably well onto how people actually make decisions.
The first group covers behaviors: physical activity, cognitive activity, social activity, a healthy diet, tobacco cessation, and reducing harmful alcohol use. The second covers management of health conditions, including hypertension, diabetes, obesity, abnormal cholesterol and hearing loss, with hearing aids offered as part of a risk reduction strategy. The third addresses environmental exposure, principally air pollution. The fourth covers multidomain interventions, meaning programs that target three or more risk factors at once.
That fourth category reflects a shift in thinking. A commentary in The Lancet Neurology describing the update notes that eleven interventions carried forward from the earlier edition were updated or validated, strengthening their position.
The Alzheimer's Association welcomed the update at its international conference in London. Sheena Aurora, the organization's vice president of medical affairs, said in the group's published statement that guidelines of this scope reflect a field that has matured. The association also said it is developing a United States-focused clinical practice guideline on risk reduction, expected in 2027.
Two of the Named Conditions Usually Produce No Symptoms at All
Hypertension and early type 2 diabetes appear on the WHO list, and both share a characteristic that shapes what a person should actually do.
Neither reliably produces symptoms. They are identified by numbers, not by how a person feels, which means the practical first step is measurement rather than lifestyle change. A blood pressure reading and an A1c test are the entry points, and both are widely available through primary care, most pharmacy clinics, and many community health centers. What to do about an abnormal result is a conversation for a clinician, not a decision to make from a guideline summary.
This is where the guidance meets a real access problem in the United States. Knowing a number requires a clinical contact. Acting on an elevated number requires affordable medication, follow-up visits, and, for smoking, cessation support. Counseling combined with FDA-approved medication improves quit rates compared with willpower alone, and most insurance plans cover cessation services without cost sharing.
For people without insurance, federally qualified health centers offer sliding scale visits, and many state and county health departments provide free blood pressure screening. State quitlines reachable at 1-800-QUIT-NOW provide free coaching and, in many states, free nicotine replacement therapy.
MedicalDaily has reported on research quantifying how much midlife vascular health matters for the number of years people live without dementia, findings that align with the conditions WHO names. That research showed an association rather than proving cause, a distinction the guidelines themselves preserve.
Where the Evidence Runs Out
The guidance is notable for what it declines to recommend, and those absences are useful for readers navigating a crowded wellness marketplace.
WHO does not recommend supplementation with vitamins B and E, omega-3 polyunsaturated fatty acids, or multivitamins and minerals as a way to reduce dementia risk in the absence of a diagnosed deficiency, citing a lack of evidence that any benefit would outweigh potential harm. Menopausal hormone therapy was likewise judged to lack sufficient evidence of benefit for preventing cognitive decline, a conclusion consistent with a WHO-commissioned review that found no evidence hormone therapy either raises or lowers dementia risk.
Readers should treat any supplement, device or program marketed as dementia prevention with skepticism unless it appears in guidance of this kind.
Nothing in the update changes clinical care overnight. Guidelines inform how health systems design programs and how clinicians frame conversations. The Alzheimer's Association guideline expected next year will be the document that translates this global guidance into United States clinical practice.
The reasonable takeaway is modest and actionable. Know your blood pressure and A1c. Address hearing loss rather than deferring it. Treat smoking cessation as a medical intervention with covered support rather than a test of willpower. And understand that none of this guarantees a future without dementia, only that these are among the few levers the evidence currently supports.
Key Questions Answered
What did WHO actually release? The second edition of its guidelines on risk reduction of cognitive decline and dementia, the first major update since 2019, covering interventions for 20 potentially modifiable risk factors.
What is new compared with the earlier version? The scope now reaches sleep, stroke, traumatic brain injury, vision impairment and HIV, and there are new recommendations on reducing air pollution exposure and on tailored programs addressing several risk factors at once.
Does this mean 45 percent of dementia is preventable for me personally? No. That figure is a population-level estimate of what share of cases might be prevented or delayed if these risk factors were addressed broadly. It does not describe individual risk reduction.
Which recommendations are easiest to act on first? Measuring blood pressure and A1c, since hypertension and early type 2 diabetes usually cause no symptoms and are identified by numbers rather than by how a person feels.
Does WHO recommend supplements for dementia prevention? No. Vitamins B and E, omega-3 fatty acids, and multivitamins are not recommended for reducing dementia risk without a diagnosed deficiency.
Where can someone get screening without insurance? Federally qualified health centers offer sliding scale visits, and many county health departments provide free blood pressure screening. State quitlines at 1-800-QUIT-NOW offer free cessation coaching.
Does this change medical care right now? Not immediately. The Alzheimer's Association has said it is developing a United States-focused clinical practice guideline on risk reduction expected in 2027.
